WO2001055391A3 - 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer - Google Patents

84p2a9: a prostate and testis specific protein highly expressed in prostate cancer Download PDF

Info

Publication number
WO2001055391A3
WO2001055391A3 PCT/US2001/002651 US0102651W WO0155391A3 WO 2001055391 A3 WO2001055391 A3 WO 2001055391A3 US 0102651 W US0102651 W US 0102651W WO 0155391 A3 WO0155391 A3 WO 0155391A3
Authority
WO
WIPO (PCT)
Prior art keywords
prostate
specific protein
highly expressed
testis specific
testis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/002651
Other languages
French (fr)
Other versions
WO2001055391A2 (en
Inventor
Aya Jakobovits
Daniel E H Afar
Pia M Challita-Eid
Elana Levin
Steve Chappell Mitchell
Rene S Hubert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Urogenesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL15087301A priority Critical patent/IL150873A0/en
Priority to DE60133627T priority patent/DE60133627T2/en
Priority to EP01910358A priority patent/EP1250434B1/en
Priority to AU2001237973A priority patent/AU2001237973B2/en
Priority to CA2398064A priority patent/CA2398064C/en
Priority to JP2001554420A priority patent/JP3946044B2/en
Application filed by Urogenesys Inc filed Critical Urogenesys Inc
Priority to AU3797301A priority patent/AU3797301A/en
Publication of WO2001055391A2 publication Critical patent/WO2001055391A2/en
Publication of WO2001055391A3 publication Critical patent/WO2001055391A3/en
Priority to IL150873A priority patent/IL150873A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A novel gene (designated 84P2A9) and its encoded protein is described. While 84P2A9 exhibits prostate and testis specific expression in normal adult tissue, it is aberrantly expressed multiple cancers including prostate, testis, kidney, brain, bone, skin, ovarian, breast, pancreas, colon, lymphocytic and lung cancers. Consequently, 84P2A9 provides a diagnostic and/or therapeutic target for cancers, and the 84P2A9 gene or fragment thereof, or its encoded protein or a fragment thereof used to elicit an immune response.
PCT/US2001/002651 2000-01-26 2001-01-26 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer Ceased WO2001055391A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DE60133627T DE60133627T2 (en) 2000-01-26 2001-01-26 84P2A9: PROSTATE AND TESTIS SPECIFIC PROTEIN HAVING HIGH EXPRESSION IN PROSTATE CANCER
EP01910358A EP1250434B1 (en) 2000-01-26 2001-01-26 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
AU2001237973A AU2001237973B2 (en) 2000-01-26 2001-01-26 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
CA2398064A CA2398064C (en) 2000-01-26 2001-01-26 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
JP2001554420A JP3946044B2 (en) 2000-01-26 2001-01-26 84P2A9: Prostate and testis specific protein highly expressed in prostate cancer
IL15087301A IL150873A0 (en) 2000-01-26 2001-01-26 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
AU3797301A AU3797301A (en) 2000-01-26 2001-01-26 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
IL150873A IL150873A (en) 2000-01-26 2002-07-23 Antibody which binds to an 84p2a9 protein and in vitro method for detecting cancer using said antibody

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17856000P 2000-01-26 2000-01-26
US60/178,560 2000-01-26

Publications (2)

Publication Number Publication Date
WO2001055391A2 WO2001055391A2 (en) 2001-08-02
WO2001055391A3 true WO2001055391A3 (en) 2002-02-21

Family

ID=22653018

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/002651 Ceased WO2001055391A2 (en) 2000-01-26 2001-01-26 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer

Country Status (12)

Country Link
US (3) US7510855B2 (en)
EP (2) EP1250434B1 (en)
JP (2) JP3946044B2 (en)
AT (2) ATE392474T1 (en)
AU (2) AU3797301A (en)
CA (1) CA2398064C (en)
CY (1) CY1111522T1 (en)
DE (2) DE60133627T2 (en)
DK (1) DK1967586T3 (en)
ES (2) ES2304126T3 (en)
IL (2) IL150873A0 (en)
WO (1) WO2001055391A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1250434B1 (en) * 2000-01-26 2008-04-16 Agensys, Inc. 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
CA2822302A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
US8168181B2 (en) * 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
US9493562B2 (en) 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
SG11201501646PA (en) * 2012-09-07 2015-04-29 Agency Science Tech & Res Peptides and their uses
WO2022013154A1 (en) * 2020-07-14 2022-01-20 Myneo Nv Method, system and computer program product for determining presentation likelihoods of neoantigens

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1074617A2 (en) * 1999-07-29 2001-02-07 Helix Research Institute Primers for synthesising full-length cDNA and their use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
TR199902053T2 (en) * 1997-02-25 2000-04-21 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use.
EP0973898A2 (en) 1997-04-10 2000-01-26 Genetics Institute, Inc. SECRETED EXPRESSED SEQUENCE TAGS (sESTs)
EP1053319A2 (en) 1998-01-28 2000-11-22 Chiron Corporation Human genes and gene expression products ii
US6013450A (en) 1998-02-20 2000-01-11 Incyte Pharmaceuticals, Inc. CAF1-related protein
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
WO2001051628A2 (en) 2000-01-14 2001-07-19 Millennium Pharmaceuticals, Inc. Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
EP1250434B1 (en) * 2000-01-26 2008-04-16 Agensys, Inc. 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
CA2395872A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001249642A1 (en) 2000-04-06 2001-10-23 Genetics Institute, Llc Polynucleotides encoding novel secreted proteins
CN1328147A (en) 2000-06-12 2001-12-26 上海博德基因开发有限公司 Polypeptide-human phosphatidase 49.06 and polynucleotide for coding it
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
AU2002210791A1 (en) 2000-07-28 2002-02-13 Compugen Inc. Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome
AU2001290548A1 (en) 2000-09-11 2002-03-26 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1325120A4 (en) 2000-10-12 2005-05-25 Nuvelo Inc NEW NUCLEIC ACIDS AND POLYPEPTIDES
AU2002253878A1 (en) 2001-01-25 2002-08-06 Gene Logic, Inc. Gene expression profiles in breast tissue

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1074617A2 (en) * 1999-07-29 2001-02-07 Helix Research Institute Primers for synthesising full-length cDNA and their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 16 April 1998 (1998-04-16), STRAUSBERG, R.: "ol10h06.s1 Soares_NFL_T_GBC_S1 Homo sapiens cDNA clone IMAGE:1523099 3' similar to TR:Q93021 Q93021 PUTATIVE TUMOR SUPPRESSOR. ;, mRNA sequence.", XP002177748 *
DATABASE EMBL 22 February 2000 (2000-02-22), ISOGAI, T ET AL.: "Homo sapiens cDNA FLJ10252 fis, clone HEMBB1000807.", XP002177749 *

Also Published As

Publication number Publication date
AU3797301A (en) 2001-08-07
ES2304126T3 (en) 2008-09-16
US20040126862A1 (en) 2004-07-01
DK1967586T3 (en) 2011-06-20
AU2001237973B2 (en) 2006-09-07
US7510855B2 (en) 2009-03-31
CA2398064C (en) 2012-12-18
ES2360155T3 (en) 2011-06-01
US8013126B2 (en) 2011-09-06
JP3946044B2 (en) 2007-07-18
ATE501255T1 (en) 2011-03-15
JP2003520605A (en) 2003-07-08
CY1111522T1 (en) 2015-08-05
CA2398064A1 (en) 2001-08-02
DE60133627T2 (en) 2009-07-30
EP1967586B1 (en) 2011-03-09
ATE392474T1 (en) 2008-05-15
DE60133627D1 (en) 2008-05-29
DE60144204D1 (en) 2011-04-21
US20090170191A1 (en) 2009-07-02
US20070054363A1 (en) 2007-03-08
US7582448B2 (en) 2009-09-01
JP5501550B2 (en) 2014-05-21
IL150873A0 (en) 2003-02-12
IL150873A (en) 2010-02-17
EP1967586A1 (en) 2008-09-10
EP1250434B1 (en) 2008-04-16
WO2001055391A2 (en) 2001-08-02
JP2006325595A (en) 2006-12-07
EP1250434A2 (en) 2002-10-23

Similar Documents

Publication Publication Date Title
IL147902A0 (en) C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
WO1999038973A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
WO2005062972A3 (en) Treatment of cancer with novel anti-il 13 monoclonal antibodies
WO1999047674A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
WO2002006317A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO1997025426A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO2000061612A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2002010382A3 (en) Trp8, trp9 and trp10, markers for cancer
WO1998045328A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
AU2002251366A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU2001240909A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2000061756A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO2001055391A3 (en) 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
WO2001090152A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2001079557A3 (en) Gtp-binding protein useful in treatment and detection of cancer
AU4174201A (en) 103p2d6: tissue specific protein highly expressed in various cancers
WO2001096391A3 (en) 55p4h4: gene expressed in various cancers
WO2002018578A3 (en) Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
WO2001059110A3 (en) 34p3d7: a tissue specific protein highly expressed in prostate cancer
WO2003020954A3 (en) 205p1b5 in treatment and detection of cancer
WO2002002772A3 (en) Human extracellular matrix (ecm)-related tumor marker
WO2001059115A3 (en) 83p5g4: a tissue specific protein highly expressed in prostate cancer
AU2002365104A1 (en) Method for the diagnosis of breast cancer diseases, associated peptides and the uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2398064

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 150873

Country of ref document: IL

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 554420

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001910358

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001237973

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2001910358

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 199648

Country of ref document: IL